Cargando…

Matrix Metalloproteinases and Minocycline: Therapeutic Avenues for Fragile X Syndrome

Fragile X syndrome (FXS) is the most common known genetic form of intellectual disability and autism spectrum disorders. FXS patients suffer a broad range of other neurological symptoms, including hyperactivity, disrupted circadian activity cycles, obsessive-compulsive behavior, and childhood seizur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siller, Saul S., Broadie, Kendal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364018/ https://www.ncbi.nlm.nih.gov/pubmed/22685676 http://dx.doi.org/10.1155/2012/124548

Ejemplares similares

Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase
por: Siller, Saul S., et al.
Publicado: (2011)

Dysregulation of BMP, Wnt, and Insulin Signaling in Fragile X Syndrome
por: Song, Chunzhu, et al.
Publicado: (2022)

ESCRT-III Membrane Trafficking Misregulation Contributes To Fragile X Syndrome Synaptic Defects
por: Vita, Dominic J., et al.
Publicado: (2017)

Genetic background mutations drive neural circuit hyperconnectivity in a fragile X syndrome model
por: Kennedy, Tyler, et al.
Publicado: (2020)

Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome
por: Laroui, Asma, et al.
Publicado: (2022)

Minocycline and MMPs: towards treatment for Fragile X syndrome
Publicado: (2011)

Fragile X mental retardation protein coordinates neuron-to-glia communication for clearance of developmentally transient brain neurons
por: Song, Chunzhu, et al.
Publicado: (2023)

Temporal Requirements of the Fragile X Mental Retardation Protein in Modulating Circadian Clock Circuit Synaptic Architecture
por: Gatto, Cheryl L., et al.
Publicado: (2009)

Fragile X mental retardation protein regulates trans-synaptic signaling in Drosophila
por: Friedman, Samuel H., et al.
Publicado: (2013)

Fragile X Mental Retardation Protein Regulates Activity-Dependent Membrane Trafficking and Trans-Synaptic Signaling Mediating Synaptic Remodeling
por: Sears, James C., et al.
Publicado: (2018)

Open-label add-on treatment trial of minocycline in fragile X syndrome
por: Paribello, Carlo, et al.
Publicado: (2010)

Excess protein synthesis in Drosophila Fragile X mutants impairs long-term memory
por: Bolduc, François V., et al.
Publicado: (2008)

Neuronal fragile X mental retardation protein activates glial insulin receptor mediated PDF-Tri neuron developmental clearance
por: Vita, Dominic J., et al.
Publicado: (2021)

Combining Lovastatin and Minocycline for the Treatment of Fragile X Syndrome: Results From the LovaMiX Clinical Trial
por: Champigny, Camille, et al.
Publicado: (2022)

Minocycline Treatment Reverses Sound Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome
por: Lovelace, Jonathan W., et al.
Publicado: (2020)

Fragile X syndrome and fragile X-associated disorders
por: Rajaratnam, Akash, et al.
Publicado: (2017)

Fragile X Syndrome
por: Saldarriaga, Wilmar, et al.
Publicado: (2014)

Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke
por: Machado, Livia S, et al.
Publicado: (2006)

Fragile X Syndrome in children
por: Acero-Garcés, David O., et al.
Publicado: (2023)

Involvement and Therapeutic Potential of the GABAergic System in the Fragile X Syndrome
por: Heulens, Inge, et al.
Publicado: (2010)

Progress toward therapeutic potential for AFQ056 in Fragile X syndrome
por: Sourial, Mary, et al.
Publicado: (2013)

Mouse models of the fragile X premutation and fragile X-associated tremor/ataxia syndrome
por: Berman, Robert F, et al.
Publicado: (2014)

Matrix metalloproteinase-2 is downregulated in sciatic nerve by streptozotocin induced diabetes and/or treatment with minocycline: Implications for nerve regeneration
por: Ali, Sumia, et al.
Publicado: (2014)

Molecular Biomarkers in Fragile X Syndrome
por: Zafarullah, Marwa, et al.
Publicado: (2019)

Developmental studies in fragile X syndrome
por: Razak, Khaleel A., et al.
Publicado: (2020)

An “Omic” Overview of Fragile X Syndrome
por: Dionne, Olivier, et al.
Publicado: (2021)

The therapeutic role of minocycline in Parkinson’s disease
por: Cankaya, Seyda, et al.
Publicado: (2019)

Closing the Gender Gap in Fragile X Syndrome: Review of Females with Fragile X Syndrome and Preliminary Research Findings
por: Bartholomay, Kristi L., et al.
Publicado: (2019)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Minocycline protects against delayed cerebral ischemia after subarachnoid hemorrhage via matrix metalloproteinase‐9 inhibition
por: Vellimana, Ananth K., et al.
Publicado: (2017)

Fragile X Syndrome
por: McLennan, Yingratana, et al.
Publicado: (2011)

Pathological Plasticity in Fragile X Syndrome
por: Martin, Brandon S., et al.
Publicado: (2012)

Senescence and the SASP: many therapeutic avenues
por: Birch, Jodie, et al.
Publicado: (2020)

Therapeutic avenues for γδ T cells in cancer
por: Costa, Gonçalo Palrão, et al.
Publicado: (2023)

DNA Methylation, Mechanisms of FMR1 Inactivation and Therapeutic Perspectives for Fragile X Syndrome
por: Nobile, Veronica, et al.
Publicado: (2021)

The challenges of clinical trials in fragile X syndrome
por: Jacquemont, Sébastien, et al.
Publicado: (2013)

An update on Cryptosporidium biology and therapeutic avenues
por: Dhal, Ajit Kumar, et al.
Publicado: (2022)

Sensory Processing Phenotypes in Fragile X Syndrome
por: Rais, Maham, et al.
Publicado: (2018)

Emerging Therapeutic Strategies for Fragile X Syndrome: Q&A
por: Alusi, Ghassan, et al.
Publicado: (2022)

Aging in fragile X syndrome
por: Utari, Agustini, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_lu09rinc39n43tekuoccfi6gei